publication . Article . 2017

Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial

Gligorov, Joseph; Curigliano, Giuseppe; Müller, Volkmar; Knoop, Ann; Jenkins, Valerie; Verma, Sunil; Osborne, Stuart; Lauer, Sabine; Machackova, Zuzana; Fallowfield, Lesley; ...
Open Access
  • Published: 23 May 2017 Journal: The Breast, volume 34, pages 89-95 (issn: 0960-9776, Copyright policy)
  • Publisher: Elsevier BV
  • Country: United Kingdom
Abstract
Aim: To assess the safety and tolerability of switching between subcutaneous (SC) and intravenous (IV) trastuzumab in the PrefHer study (NCT01401166).\ud \ud Patients and methods: Patients with HER2-positive early breast cancer completed (neo)adjuvant chemotherapy and were randomised to receive four cycles of SC trastuzumab, via single-use injection device (SID; Cohort 1) or hand-held syringe (Cohort 2), followed by four cycles of IV, or vice versa (the crossover period presented here) as part of their 18 standard cycles of adjuvant trastuzumab treatment. Adverse events (AEs) were reported using standard criteria.\ud \ud Results: Overall, fewer AEs were reported...
Subjects
free text keywords: Surgery, General Medicine, Gynecology, medicine.medical_specialty, medicine, Breast cancer, medicine.disease, Chemotherapy, medicine.medical_treatment, HER2/neu, biology.protein, biology, Trastuzumab, medicine.drug, business.industry, business, Adjuvant, Internal medicine, Tolerability, Cohort, Oncology, Adverse effect, R

[1] [2] [3] [4] [5] [6] Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii11-19.

Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue